{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:33:55Z","timestamp":1773257635351,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s43440-025-00808-4","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:00:51Z","timestamp":1769061651000},"page":"558-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7140-8175","authenticated-orcid":false,"given":"Taichi","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy D.","family":"Kreskow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-1927","authenticated-orcid":false,"given":"Alexander L. R.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7746-6351","authenticated-orcid":false,"given":"Catherine L.","family":"Blumhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8626-2089","authenticated-orcid":false,"given":"Justin J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-5667","authenticated-orcid":false,"given":"Andrew J.","family":"Mannes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Ba\u010dkonja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-7412","authenticated-orcid":false,"given":"Carlos A.","family":"Zarate Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9481-7836","authenticated-orcid":false,"given":"Leorey N.","family":"Saligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"808_CR1","doi-asserted-by":"crossref","unstructured":"Beckers E, Hermans K, Van Tubergen A, Boonen A. Fatigue in patients with rheumatic and musculoskeletal diseases: a scoping review on definitions, measurement instruments, determinants, consequences and interventions. RMD Open. 2023;9(3).","DOI":"10.1136\/rmdopen-2023-003056"},{"key":"808_CR2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ijc.34791","volume":"154","author":"ME Schmidt","year":"2024","unstructured":"Schmidt ME, Maurer T, Behrens S, Seibold P, Obi N, Chang-Claude J, et al. Cancer-related fatigue: towards a more targeted approach based on classification by biomarkers and psychological factors. Int J Cancer 2024;154(6):1011\u201318.","journal-title":"Int J Cancer"},{"key":"808_CR3","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1093\/rheumatology\/kead020","volume":"62","author":"T Thibault","year":"2023","unstructured":"Thibault T, Bourredjem A, Maurier F, Wahl D, Muller G, Aumaitre O, et al. The mediating effect of fatigue in impaired quality of life in systemic lupus erythematosus: mediation analysis of the french equal cohort. Rheumatology 2023;62:3051\u201358.","journal-title":"Rheumatology"},{"key":"808_CR4","doi-asserted-by":"crossref","unstructured":"Vahratian A, Lin JS, Bertolli J, Unger ER. Myalgic encephalomyelitis\/chronic fatigue syndrome in adults: United States, 2021-2022. NCHS Data Brief. 2023(488):1\u20138.","DOI":"10.15620\/cdc:134504"},{"key":"808_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3899\/jrheum.2023-0698.C1","volume":"51","author":"J Weinstein","year":"2024","unstructured":"Weinstein J, Rosero S, Seabury J, Varma A, Engebrecht C, Khosa S, et al. Patient-reported impact of symptoms in fibromyalgia (Prism-Fm). J Rheumatol 2024;51(6):628\u201336.","journal-title":"J Rheumatol"},{"issue":"9","key":"808_CR6","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3899\/jrheum.120724","volume":"39","author":"S Hewlett","year":"2012","unstructured":"Hewlett S, Choy E, Kirwan J.Furthering our understanding of fatigue in rheumatoid arthritis. J Rheumatol. 2012;39(9):1775\u201377.","journal-title":"J Rheumatol"},{"key":"808_CR7","doi-asserted-by":"publisher","first-page":"103971","DOI":"10.1016\/j.msard.2022.103971","volume":"65","author":"HH Le","year":"2022","unstructured":"Le HH, Ken-Opurum J, LaPrade A, Maculaitis MC, Sheehan JJ. Assessment of economic burden of fatigue in adults with multiple sclerosis: an analysis of us national health and wellness survey data. Mult Scler Relat Disord. 2022;65:103971.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"808_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3904\/kjim.2015.219","volume":"32","author":"JH Koh","year":"2017","unstructured":"Koh JH, Kwok SK, Lee J, Park SH.Autonomic dysfunction in primary Sjogren\u2019s syndrome: a prospective cohort analysis of 154 Korean Patients. Korean J Intern Med. 2017;32(1):165\u201373.","journal-title":"Korean J Intern Med"},{"issue":"9","key":"808_CR9","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1007\/s12035-016-0170-2","volume":"54","author":"G Morris","year":"2017","unstructured":"Morris G, Anderson G, Maes M.Hypothalamic-pituitary-adrenal hypofunction in myalgic encephalomyelitis (Me)\/chronic fatigue syndrome (Cfs) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways. Mol Neurobiol. 2017;54(9):6806\u201319.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"808_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41398-018-0161-3","volume":"8","author":"LR Feng","year":"2018","unstructured":"Feng LR, Fernandez-Martinez JL, Zaal KJM, deAndres-Galiana EJ, Wolff BS, Saligan LN.Mglur5 mediates post-radiotherapy fatigue development in cancer patients. Transl Psychiatry. 2018;8(1):110.","journal-title":"Transl Psychiatry"},{"key":"808_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2040622315579059","volume":"6","author":"ND Iadarola","year":"2015","unstructured":"Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis 2015;6:97\u2013114.","journal-title":"Ther Adv Chronic Dis"},{"key":"808_CR12","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1177\/0271678X19886316","volume":"40","author":"SE Holmes","year":"2020","unstructured":"Holmes SE, Gallezot JD, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, et al. Measuring the effects of ketamine on Mglur5 using [(18)F]Fpeb and pet. J Cereb Blood Flow Metab 2020;40:2254\u201364.","journal-title":"J Cereb Blood Flow Metab"},{"key":"808_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2016.01.009","volume":"194","author":"LN Saligan","year":"2016","unstructured":"Saligan LN, Luckenbaugh DA, Slonena EE, Machado-Vieira R, Zarate Jr CA. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J Affect Disord. 2016;194:115\u201319.","journal-title":"J Affect Disord"},{"key":"808_CR14","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170(10):1134\u201342.","journal-title":"Am J Psychiatry"},{"key":"808_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","volume":"26","author":"TP Su","year":"2023","unstructured":"Su TP, Li CT, Lin WC, Wu HJ, Tsai SJ, Bai YM, et al. A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation. Int J Neuropsychopharmacol 2023;26(5):331\u201339.","journal-title":"Int J Neuropsychopharmacol"},{"key":"808_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ejon.2013.06.002","volume":"17","author":"A Dhruva","year":"2013","unstructured":"Dhruva A, Aouizerat BE, Cooper B, Paul SM, Dodd M, West C, et al. Differences in morning and evening fatigue in oncology patients and their family caregivers. Eur J Oncol Nurs 2013;17(6):841\u201348.","journal-title":"Eur J Oncol Nurs"},{"key":"808_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","volume":"79","author":"TG Rhee","year":"2022","unstructured":"Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry 2022;79(12):1162\u201372.","journal-title":"JAMA Psychiatry"},{"key":"808_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"808_CR19","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/art.24311","volume":"59","author":"B Segal","year":"2008","unstructured":"Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, et al. Prevalence, severity, and predictors of fatigue in subjects with primary sjogren\u2019s syndrome. Arthritis Rheum 2008;59(12):1780\u201387.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"808_CR20","first-page":"1745","volume":"20","author":"J Kamath","year":"2012","unstructured":"Kamath J, Feinn R, Winokur A.Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study. Support Care Cancer. 2012;20(8):1745\u201353.","journal-title":"Support Care Cancer"},{"key":"808_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/978-1-4419-0318-1","volume-title":"Mixed-effects models in S and S-Plus","author":"JC Pinheiro","year":"2000","unstructured":"Pinheiro JC, Bates DM. Mixed-effects models in S and S-Plus. vol. xvi. New York: Springer; 2000:xvi. p. 528."},{"key":"808_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1176\/appi.focus.22020004","volume":"20","author":"JB Dwyer","year":"2022","unstructured":"Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Focus (Am Psychiatr Publ). 2022;20(2):241\u201351.","journal-title":"Focus"},{"key":"808_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/YCT.0000000000000560","volume":"35","author":"M Finnegan","year":"2019","unstructured":"Finnegan M, Galligan T, Ryan K, Shanahan E, Harkin A, Daly L, et al. Ketamine versus midazolam for depression relapse prevention following successful electroconvulsive therapy: a randomized controlled pilot trial. J ECT 2019;35(2):115\u201321.","journal-title":"J ECT"},{"key":"808_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","volume":"175","author":"MF Grunebaum","year":"2018","unstructured":"Grunebaum MF, Galfalvy HC, Choo TH, Keilp JG, Moitra VK, Parris MS, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry 2018;175(4):327\u201335.","journal-title":"Am J Psychiatry"},{"key":"808_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bdi.12487","volume":"19","author":"MF Grunebaum","year":"2017","unstructured":"Grunebaum MF, Ellis SP, Keilp JG, Moitra VK, Cooper TB, Marver JE, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord 2017;19(3):176\u201383.","journal-title":"Bipolar Disord"},{"key":"808_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jad.2021.12.055","volume":"300","author":"A Hochschild","year":"2022","unstructured":"Hochschild A, Keilp JG, Madden SP, Burke AK, Mann JJ, Grunebaum MF. Ketamine vs Midazolam: mood improvement reduces suicidal ideation in depression. J Affect Disord. 2022;300:10\u201316.","journal-title":"J Affect Disord"},{"key":"808_CR27","doi-asserted-by":"crossref","unstructured":"Wen J, Wang W, Liu K, Sun X, Zhou J, Hu H, et al. The psychological side of menopause: evidence from the comorbidity network of menopausal, anxiety, and depressive symptoms. Menopause 2024.","DOI":"10.1097\/GME.0000000000002406"},{"issue":"3","key":"808_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pmn.2024.02.003","volume":"25","author":"A Saravanan","year":"2024","unstructured":"Saravanan A, Bajaj P, Matthews HL, Tell D, Starkweather A, Janusek L.Fatigue and depressive mood in chronic low back pain. Pain Manag Nurs. 2024;25(3):225\u201330.","journal-title":"Pain Manag Nurs"},{"key":"808_CR29","doi-asserted-by":"crossref","unstructured":"Goto T, Von Ah D, Li X, Xiang L, Kwiat C, Nguyen C, et al. Brain-derived neurotrophic factor Rs6265 polymorphism is associated with severe cancer-related fatigue and neuropathic pain in female cancer survivors. J Cancer Surviv 2023.","DOI":"10.1007\/s11764-023-01426-w"},{"key":"808_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bja.2021.12.042","volume":"128","author":"Y Oshima","year":"2022","unstructured":"Oshima Y, Sano M, Kajiwara I, Ichimaru Y, Itaya T, Kuramochi T, et al. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. Br J Anaesth 2022;128(4):679\u201390.","journal-title":"Br J Anaesth"},{"key":"808_CR31","doi-asserted-by":"publisher","first-page":"109767","DOI":"10.1016\/j.neuropharm.2023.109767","volume":"242","author":"L Caffino","year":"2024","unstructured":"Caffino L, Mottarlini F, Piva A, Rizzi B, Fumagalli F, Chiamulera C. Temporal dynamics of bdnf signaling recruitment in the rat prefrontal cortex and hippocampus following a single infusion of a translational dose of ketamine. Neuropharmacology. 2024;242:109767.","journal-title":"Neuropharmacology"},{"key":"808_CR32","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41401-023-01201-8","volume":"45","author":"H Ma","year":"2024","unstructured":"Ma H, Li JF, Qiao X, Zhang Y, Hou XJ, Chang HX, et al. Sigma-1 receptor activation mediates the sustained antidepressant effect of ketamine in mice via increasing Bdnf levels. Acta Pharmacol Sin 2024;45(4):704\u201313.","journal-title":"Acta Pharmacol Sin"},{"key":"808_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41398-020-00990-4","volume":"10","author":"LR Feng","year":"2020","unstructured":"Feng LR, Juneau P, Regan JM, Liwang J, Alshawi S, Wang A, et al. Brain-derived neurotrophic factor polymorphism val66met protects against cancer-related fatigue. Transl Psychiatry 2020;10(1):302.","journal-title":"Transl Psychiatry"},{"key":"808_CR34","doi-asserted-by":"publisher","first-page":"932235","DOI":"10.3389\/fpsyt.2022.932235","volume":"13","author":"L Chu","year":"2022","unstructured":"Chu L, Sun X, Jia X, Li D, Gao P, Zhang Y, et al. The relationship among bdnf val66met polymorphism, plasma bdnf level, and trait anxiety in chinese patients with panic disorder. Front Psychiatry. 2022;13:932235.","journal-title":"Front Psychiatry"},{"issue":"1","key":"808_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.brainresbull.2009.06.022","volume":"81","author":"E Ozan","year":"2010","unstructured":"Ozan E, Okur H, Eker C, Eker OD, Gonul AS, Akarsu N.The effect of depression, bdnf gene val66met polymorphism and gender on serum bdnf levels. Brain Res Bull. 2010;81(1):61\u201365.","journal-title":"Brain Res Bull"},{"issue":"10","key":"808_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","volume":"11","author":"JE Bower","year":"2014","unstructured":"Bower JE.Cancer-related fatigue\u2013mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597\u2013609.","journal-title":"Nat Rev Clin Oncol"},{"key":"808_CR37","doi-asserted-by":"crossref","unstructured":"Bradley LA. Pathophysiology of Fibromyalgia. Am J Med. 2009;122(12 Suppl):S22\u201330.","DOI":"10.1016\/j.amjmed.2009.09.008"},{"key":"808_CR38","doi-asserted-by":"crossref","unstructured":"Cortes Rivera M, Mastronardi C, Silva-Aldana CT, Arcos-Burgos M, Lidbury BA. Myalgic encephalomyelitis\/chronic fatigue syndrome: a comprehensive review. Diagnostics (Basel). 2019;9(3).","DOI":"10.3390\/diagnostics9030091"},{"key":"808_CR39","doi-asserted-by":"crossref","unstructured":"Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008(182):335\u201360.","DOI":"10.1007\/978-3-540-74806-9_16"},{"key":"808_CR40","doi-asserted-by":"crossref","unstructured":"Kawka L, Schlencker A, Mertz P, Martin T, Arnaud L. Fatigue in systemic lupus erythematosus: an update on its impact, determinants and therapeutic management. J Clin Med. 2021;10(17).","DOI":"10.3390\/jcm10173996"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00808-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00808-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00808-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:35:08Z","timestamp":1773196508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00808-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00808-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co\u2013inventor on a patent for the use of (2R,6R)\u2013hydroxynorketamine, (S\u2013dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S\u2013ketamine in the treatment of depression and neuropathic pain; and as a co\u2013inventor on a patent application for the use of (2R,6R)\u2013hydroxynorketamine and (2S,6S)\u2013hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post\u2013traumatic stress disorder. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}